5,283 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Healthcare of Ontario Pension Plan Trust Fund

Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to its most recent filing with the SEC. The firm acquired 5,283 shares of the company’s stock, valued at approximately $1,763,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Ashton Thomas Securities LLC bought a new position in Medpace in the third quarter valued at about $37,000. DT Investment Partners LLC acquired a new position in Medpace during the 2nd quarter valued at about $41,000. Capital Performance Advisors LLP bought a new position in shares of Medpace in the 3rd quarter valued at about $46,000. Ashton Thomas Private Wealth LLC bought a new position in shares of Medpace in the 2nd quarter valued at about $52,000. Finally, International Assets Investment Management LLC acquired a new stake in shares of Medpace during the 2nd quarter worth approximately $61,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Stock Performance

Shares of MEDP opened at $340.63 on Monday. The stock has a 50 day simple moving average of $337.82 and a 200 day simple moving average of $370.98. Medpace Holdings, Inc. has a 52-week low of $268.80 and a 52-week high of $459.77. The firm has a market capitalization of $10.59 billion, a PE ratio of 29.83, a P/E/G ratio of 1.88 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 21st. The company reported $3.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.24. The company had revenue of $533.32 million during the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The firm’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.22 earnings per share. Equities research analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Redburn Atlantic initiated coverage on shares of Medpace in a research note on Monday, October 14th. They issued a “buy” rating and a $404.00 price objective on the stock. Robert W. Baird raised their price target on Medpace from $349.00 to $354.00 and gave the stock a “neutral” rating in a research report on Monday, November 25th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and cut their target price for the company from $415.00 to $345.00 in a research note on Wednesday, September 25th. Finally, Baird R W lowered Medpace from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 23rd. Seven analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $380.56.

Medpace Company Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.